Applied Therapeutics Inc (OQ:APLT)

Apr 15, 2024 07:00 am ET
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the appointment of...
Apr 04, 2024 07:00 am ET
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present...
Mar 28, 2024 04:30 pm ET
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food...
Mar 06, 2024 07:00 am ET
Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported...
Feb 28, 2024 08:05 am ET
Applied Therapeutics Announces $100 Million Private Placement
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it has entered...
Feb 28, 2024 08:00 am ET
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food...
Feb 15, 2024 07:00 am ET
Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced positive interim...
Jan 09, 2024 08:31 am ET
Thinking about buying stock in Angion Biomedica, Ardelyx, AMC Entertainment, Applied Therapeutics, or Wisekey International Holding ?
NEW YORK, Jan. 9, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ELTX, ARDX, AMC, APLT, and WKEY.
Jan 04, 2024 04:05 pm ET
Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the topline results...
Jan 04, 2024 08:31 am ET
Thinking about buying stock in Omega Therapeutics, Eli Lilly And Co, Cisco Systems, Applied Therapeutics, or Brooge Energy?
NEW YORK, Jan. 4, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OMGA, LLY, CSCO, APLT, and BROG.
Jan 03, 2024 08:31 am ET
Thinking about buying stock in Dyne Therapeutics, Applied Therapeutics, ON Semiconductor, Mereo BioPharma, or Neximmune?
NEW YORK, Jan. 3, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DYN, APLT, ON, MREO, and NEXI.
Jan 03, 2024 07:00 am ET
Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it has submitted a...
Dec 19, 2023 08:31 am ET
Thinking about buying stock in Compugen, Hanryu Holdings, Super Micro Computer, Coterra Energy, or Applied Therapeutics?
NEW YORK, Dec. 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGEN, HRYU, SMCI, CTRA, and APLT.
Dec 11, 2023 08:31 am ET
Thinking about buying stock in Applied Therapeutics, Golden Heaven Group, Smartsheet Inc, Eneti Inc, or Hello Group?
NEW YORK, Dec. 11, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APLT, GDHG, SMAR, NETI, and MOMO.
Dec 08, 2023 08:31 am ET
Thinking about buying stock in Applied Therapeutics, Golden Heaven Group, Smartsheet Inc, Eneti Inc, or Hello Group?
NEW YORK, Dec. 8, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APLT, GDHG, SMAR, NETI, and MOMO.
Nov 22, 2023 08:31 am ET
Thinking about trading options or stock in Verizon Communications, Applied Therapeutics, Adobe, VinFast Auto, or ArcelorMittal?
NEW YORK, Nov. 22, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VZ, APLT, ADBE, VFS, and MT.
Nov 09, 2023 08:31 am ET
Thinking about buying stock in Applied Therapeutics, Motus GI Holdings, Plug Power, Kinnate Biopharma, or Virgin Galactic Holdings?
NEW YORK, Nov. 9, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APLT, MOTS, PLUG, KNTE, and SPCE.
Nov 09, 2023 07:30 am ET
Applied Therapeutics Reports Third Quarter 2023 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Nov 08, 2023 08:31 am ET
Thinking about buying stock in PaxMedica, Applied Therapeutics, Tharimmune, Singular Genomics Systems, or BIOLASE?
NEW YORK, Nov. 8, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PXMD, APLT, THAR, OMIC, and BIOL.
Nov 07, 2023 08:31 am ET
Thinking about buying stock in Applied Therapeutics, Coherus Biosciences, Tempest Therapeutics, Bluegreen Vacations Holding, or Adams Resources & Energy?
NEW YORK, Nov. 7, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APLT, CHRS, TPST, BVH, and AE.
Nov 02, 2023 07:00 am ET
Applied Therapeutics to Present at the UBS Biopharma Conference 2023
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present...
Nov 01, 2023 07:00 am ET
Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will host a...
Sep 28, 2023 07:00 am ET
Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will participate...
Sep 25, 2023 09:31 am ET
Thinking about buying stock in Nikola Corp, Eos Energy Enterprises, Applied Therapeutics, Tango Therapeutics, or Cabaletta Bio?
NEW YORK, Sept. 25, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKLA, EOSE, APLT, TNGX, and CABA.
Sep 06, 2023 07:00 am ET
Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced successful...
Aug 10, 2023 07:00 am ET
Applied Therapeutics Reports Second Quarter 2023 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Jul 25, 2023 07:00 am ET
Applied Therapeutics Provides Regulatory Update on Galactosemia Program
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update...
Jun 27, 2023 08:14 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Applied Therapeutics, Inc. (NASDA
NEW YORK, June 27, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Applied Therapeutics, Inc. (NASDAQ: APLT) concerning possible breaches of fiduciary duty. To obtain additional information, go to:
Jun 27, 2023 08:30 am ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Applied Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, June 27, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Applied Therapeutics, Inc. (NASDAQ: APLT).
Jun 22, 2023 07:00 am ET
Applied Therapeutics to Present Baseline Data on the Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at the 2023 Annual Meeting of the American Diabetes Association
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced multiple...
Jun 15, 2023 07:00 am ET
Applied Therapeutics to Present Data on AT-007 (Govorestat) Treatment in SORD Deficiency at the 2023 Annual Meeting of the Peripheral Nerve Society
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced multiple oral...
May 25, 2023 07:00 am ET
Govorestat (AT-007) Receives Orphan Medicinal Product Designation from the EMA for Treatment of SORD Deficiency
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that AT-007...
May 11, 2023 07:00 am ET
Applied Therapeutics Reports First Quarter 2023 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Apr 24, 2023 07:00 am ET
Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced results from the...
Apr 24, 2023 07:00 am ET
Applied Therapeutics, Inc. Announces $30 Million Private Placement of Equity
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it...
Apr 19, 2023 02:38 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Applied Therapeutics, Inc. (NASDA
NEW YORK, April 19, 2023 /PRNewswire/ --  Levi & Korsinsky announces that it has commenced an investigation of Applied Therapeutics, Inc. (NASDAQ: APLT) concerning possible breaches of fiduciary duty. To obtain additional information, go to:
Mar 23, 2023 06:30 am ET
Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results...
Mar 01, 2023 07:00 am ET
Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will...
Feb 16, 2023 07:00 am ET
Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced positive sorbitol...
Feb 09, 2023 07:00 am ET
Applied Therapeutics to Present at the SVB Securities Global Biopharma Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present...
Jan 04, 2023 06:00 am ET
Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (Govorestat) in Europe
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a partnership with...
Dec 14, 2022 09:47 am ET
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Applied Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
NEW YORK, Dec. 14, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Applied Therapeutics, Inc. (NASDAQ: APLT).
Nov 09, 2022 07:00 am ET
Applied Therapeutics Reports Third Quarter 2022 Financial Results
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported...
Oct 31, 2022 07:00 am ET
Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced multiple data...
Oct 25, 2022 07:00 am ET
Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced full enrollment in...
Oct 06, 2022 07:00 am ET
Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Continue to 18 Months in Blinded Format
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the...
Aug 12, 2022 07:00 am ET
Applied Therapeutics Reports Second Quarter 2022 Financial Results
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported...
Jul 28, 2022 07:00 am ET
Applied Therapeutics to Sponsor and Present at the 2022 Galactosemia Foundation Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced its sponsorship and...
Jun 22, 2022 10:12 pm ET
Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the...
Jun 22, 2022 04:10 pm ET
Applied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that...
Jun 03, 2022 07:00 am ET
Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced designation of...
May 19, 2022 07:00 am ET
Applied Therapeutics to Present at the UBS Global Healthcare Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will...
May 12, 2022 06:59 am ET
Applied Therapeutics Reports First Quarter 2022 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
May 05, 2022 07:30 am ET
Applied Therapeutics to Present Data on AT-007 Treatment in SORD Deficiency at the 2022 Annual Meeting of the Peripheral Nerve Society
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced presentations at the...
Apr 04, 2022 07:30 am ET
Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster presentations...
Mar 25, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Corcept, Verra, Core Scientific, and Applied Therapeutics and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Corcept Therapeutics, Inc. (NASDAQ: CORT), Verra Mobility Corp. (NASDAQ: VRRM), Core Scientific, Inc. (NASDAQ: CORZ), and...
Mar 20, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Core Scientific, Applied Therapeutics, and Lilium and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Core Scientific, Inc. (NASDAQ: CORZ), Applied Therapeutics, Inc. (NASDAQ: APLT), and Lilium N.V. (NASDAQ: LILM). Our...
Mar 16, 2022 07:30 am ET
Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced their abstract...
Mar 14, 2022 09:34 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Verra, Corcept, Core Scientific, and Applied Therapeutics and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Verra Mobility Corp. (NASDAQ: VRRM), Corcept Therapeutics, Inc. (NASDAQ: CORT), Core Scientific, Inc. (NASDAQ: CORZ), and...
Mar 10, 2022 07:30 am ET
Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Mar 09, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Verra and Applied Therapeutics and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Verra Mobility Corp. (NASDAQ: VRRM) and Applied Therapeutics, Inc. (NASDAQ: APLT). Our investigations concern whether these...
Mar 04, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Cronos, Applied Therapeutics, Everbridge, and Agrify and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cronos Group, Inc. (NASDAQ: CRON), Applied Therapeutics, Inc. (NASDAQ: APLT), Everbridge, Inc. (NASDAQ: EVBG), and Agrify...
Mar 01, 2022 07:00 am ET
Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will...
Feb 28, 2022 07:30 am ET
Applied Therapeutics Supports 15th Annual Rare Disease Day
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today is recognizing the 15th Annual...
Feb 11, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Applied Therapeutics, Gatos, Anavex, and Greenidge and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Applied Therapeutics, Inc. (NASDAQ: APLT), Gatos Silver (NYSE: GATO), Anavex Life Sciences Corp. (NASDAQ: AVXL), and...
Feb 10, 2022 07:00 am ET
Applied Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present...
Jan 31, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Embark, Affirm, Applied Therapeutics, and Gatos and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Embark Technology, Inc. (NASDAQ: EMBK), Affirm Holdings, Inc. (NASDAQ: AFRM), Applied Therapeutics, Inc. (NASDAQ: APLT), and...
Jan 31, 2022 01:35 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Applied Therapeutics, Inc. (APLT) Investors to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations
Hagens Berman urges Applied Therapeutics, Inc. (NASDAQ: APLT) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...
Jan 21, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Is Investigating Medallion Financial, Clarivate, TaskUs, and Applied Therapeutics and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Medallion Financial Corporation (NASDAQ: MFIN), Clarivate Plc (NYSE: CLVT), TaskUs (NASDAQ: TASK), and Applied Therapeutics,...
Jan 18, 2022 09:00 pm ET
APPLIED THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Applied Therapeutics, Inc. on Behalf of Applied Therapeutics Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) on behalf of Applied Therapeutics stockholders. Our investigation concerns whether Applied Therapeutics has violated the federal securities laws and/or engaged in other unlawful business practices.
Jan 18, 2022 02:18 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Applied Therapeutics, Inc. (APLT) Investors to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations
Hagens Berman urges Applied Therapeutics, Inc. (NASDAQ: APLT) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...
Jan 14, 2022 08:31 am ET
APLT INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Applied Therapeutics, Inc. (APLT) Investors to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations
SAN FRANCISCO, Jan. 14, 2022 /PRNewswire/ -- Hagens Berman urges Applied Therapeutics, Inc. (NASDAQ: APLT) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.
Jan 13, 2022 05:56 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Applied Therapeutics, Inc. (APLT) Investors to Contact Firm’s Attorneys, Firm Investigating Possible Securities Law Violations
Hagens Berman urges Applied Therapeutics, Inc. (NASDAQ: APLT) investors with significant losses to submit your losses now.   The firm is investigating possible securities law violations and certain investors may have valuable claims. Visit:...
Jan 10, 2022 03:37 pm ET
SHAREHOLDER ALERT: Robbins LLP Investigates Applied Therapeutics, Inc. (APLT) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP is investigating Applied Therapeutics, Inc. (NASDAQ: APLT) to determine whether certain Applied Therapeutics officers and directors violated securities laws and breached fiduciary duties to shareholders. Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops
Jan 06, 2022 12:06 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Therapeutics, Inc. - APLT
Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. (“Applied” or the “Company”) (NASDAQ: APLT). Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980....
Jan 06, 2022 11:45 am ET
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Applied Therapeutics, Inc. (APLT) Investigation
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT). Investors who purchased Applied Therapeutics shares are encouraged to obtain additional information and assist the investigation by visiting the firm’s site:
Jan 03, 2022 07:00 am ET
Applied Therapeutics Provides Regulatory Update on Galactosemia Program
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update...
Dec 16, 2021 07:00 am ET
Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a...
Nov 18, 2021 07:00 am ET
Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, has announced a symposium and poster...
Nov 12, 2021 07:00 am ET
Applied Therapeutics Reports Third Quarter 2021 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Oct 25, 2021 07:00 am ET
Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported biomarker data from a...
Oct 18, 2021 07:00 am ET
Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported additional biomarker...
Sep 09, 2021 07:00 am ET
Applied Therapeutics Reports Initial Pediatric Biomarker Data from ACTION-Galactosemia Kids
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported initial biomarker...
Aug 12, 2021 07:00 am ET
Applied Therapeutics Reports Second Quarter 2021 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Jun 28, 2021 07:00 am ET
Applied Therapeutics Added to Russell Microcap® Index
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company has...
Jun 25, 2021 12:05 pm ET
Applied Therapeutics Announces Presentation of Data on the Prevalence of Diabetic Cardiomyopathy at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced data presentations...
Jun 21, 2021 07:00 am ET
Applied Therapeutics to Present on Diabetic Cardiomyopathy and Prevalence of Disease at the 81st Scientific Sessions of the 2021 Annual Meeting of the American Diabetes Association
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a Product Theater...
Jun 17, 2021 07:00 am ET
Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food...
Jun 01, 2021 07:00 am ET
Applied Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present...
May 19, 2021 07:00 am ET
Applied Therapeutics to Present at the UBS Global Healthcare Virtual Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present...
May 11, 2021 07:00 am ET
Applied Therapeutics Reports First Quarter 2021 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT) (“Applied Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical...
Apr 07, 2021 07:00 am ET
Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced a poster...
Mar 18, 2021 07:00 am ET
Applied Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Mar 16, 2021 07:00 am ET
Applied Therapeutics to Host Virtual Rare Disease Forum
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it will host a...
Feb 23, 2021 07:00 am ET
Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present...
Feb 22, 2021 07:00 am ET
Applied Therapeutics, Inc. Announces Closing of Public Offering
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the...
Feb 11, 2021 06:51 pm ET
Applied Therapeutics, Inc. Announces Pricing of Public Offering of 3,000,000 Shares of Common Stock
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the...
Feb 10, 2021 04:07 pm ET
Applied Therapeutics, Inc. Announces Offering of 3,000,000 Shares of Common Stock
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that...
Feb 04, 2021 06:57 pm ET
SHAREHOLDER ALERT: Barr Law Group Investigating NK, PS, JELD, and APLT; Shareholders are Encouraged to Contact the Firm
National law firm Barr Law Group is investigating the actions of the officers and board of directors of NantKwest, Inc., Pluralsight, Inc., JELD-WEN Holding, Inc., and Applied Therapeutics, Inc.  If you are a current owner of shares of any of these...
Feb 01, 2021 07:00 am ET
Applied Therapeutics Announces Restart of Pediatric Galactosemia Study
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the FDA has...
Dec 15, 2020 08:00 am ET
Applied Therapeutics to be Added to NASDAQ Biotechnology Index
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the Company was...
Dec 09, 2020 08:15 am ET
Applied Therapeutics Announces Launch of Galactosemia Awareness and Education Initiative
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the launch...
Dec 09, 2020 07:00 am ET
Applied Therapeutics Announces MRS Data from ACTION-Galactosemia Study
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced magnetic resonance...
Nov 12, 2020 07:00 am ET
Applied Therapeutics Reports Third Quarter 2020 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Nov 09, 2020 07:00 am ET
Applied Therapeutics Announces Presentation of Pre-Clinical Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2020
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today  presentation of...
Oct 21, 2020 07:00 am ET
Applied Therapeutics to Present Data on AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2020 Annual Meeting
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present...
Oct 06, 2020 08:00 am ET
SHAREHOLDER ALERT: APLT AND LEGN Being Investigated by Block & Leviton LLP for Possible Securities Laws Violations; Shareholders Should Contact the Firm
Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it is investigating whether Applied Therapeutics, Inc. (NASDAQ: APLT) and Legend Biotech Corporation (NASDAQ: LEGN) may be liable for...
Oct 05, 2020 01:00 pm ET
180 Life Science Corp. Announces New Board of Directors Appointments
KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced the signing of a definitive agreement to acquire 180 Life Sciences Corp. ("180 Life Sciences"), a clinical-stage...
Sep 24, 2020 08:00 am ET
FDA Grants AT-007 Pediatric Rare Disease Designation and Orphan Designation for Treatment of PMM2-CDG
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that the U.S. Food...
Sep 17, 2020 07:00 am ET
Applied Therapeutics to Present Data on AT-001 for Treatment of Diabetic Cardiomyopathy at 56th Annual Meeting of the European Association for the Study of Diabetes
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present...
Sep 02, 2020 07:00 am ET
Applied Therapeutics to Present at Citi and Baird Investor Conferences
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present...
Sep 01, 2020 01:53 pm ET
APPLIED THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Applied Therapeutics, Inc. on Behalf of Applied Therapeutics Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Applied Therapeutics, Inc. (NASDAQ: APLT) on behalf of Applied Therapeutics stockholders. Our investigation concerns whether...
Sep 01, 2020 08:00 am ET
SHAREHOLDER ALERT: Block & Leviton LLP Reminds Investors that it Is Investigating APLT and POR for Possible Securities Laws Violations; Shareholders Should Contact the Firm
Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, reminds investors that it is investigating whether Applied Therapeutics, Inc. (NASDAQ: APLT) and Portland General Electric Company (NYSE: POR) may be liable for...
Aug 29, 2020 07:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Therapeutics, Inc. - APLT
Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. (“Applied” or the “Company”) (NASDAQ: APLT).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Aug 25, 2020 10:33 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Applied Therapeutics, Inc. - APLT
Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. (“Applied” or the “Company”) (NASDAQ: APLT).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Aug 21, 2020 05:00 pm ET
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Applied Therapeutics, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm –
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) resulting from allegations that Applied Therapeutics may have issued...
Aug 21, 2020 08:00 am ET
Applied Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm advises Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of...
Aug 20, 2020 05:29 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Therapeutics, Inc. - APLT
Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. (“Applied” or the “Company”) (NASDAQ: APLT).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext....
Aug 20, 2020 04:00 pm ET
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ:
Aug 20, 2020 01:00 pm ET
The Law Offices of Frank R. Cruz Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation on behalf of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ:
Aug 20, 2020 11:38 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applied Therapeutics, Inc. (“Applied Therapeutics” or “the Company”) (NASDAQ:
Aug 19, 2020 07:35 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Applied Therapeutics, Inc. (APLT) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT) investors concerning the Company’s possible violations of federal securities laws.
Aug 19, 2020 01:29 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Applied Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Applied Therapeutics, Inc. (“Applied Therapeutics” or “the Company”) (NASDAQ:
Aug 19, 2020 09:55 am ET
EQUITY ALERT: ROSEN, A LEADING AND RANKED LAW FIRM, Announces Investigation of Securities Claims Against Applied Therapeutics, Inc. – APLT
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT) resulting from allegations that Applied Therapeutics may have issued materially misleading business information to the investing public.
Aug 18, 2020 06:41 pm ET
SHAREHOLDER ALERT: Block & Leviton LLP Investigating Applied Therapeutics, Inc. for Possible Securities Laws Violations; Shareholders Should Contact the Firm
Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, is investigating whether Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of its executives may be liable for securities fraud. If you purchased or acquired...
Aug 11, 2020 07:00 am ET
Applied Therapeutics Reports Second Quarter 2020 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Jul 17, 2020 07:00 am ET
Applied Therapeutics to Present Data on AT-007 for Treatment of Galactosemia at the Galactosemia Foundation 2020 Virtual Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced presentations covering the...
Jul 06, 2020 06:00 am ET
Applied Therapeutics Takes Action Against Fraudulent “Short Report”
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced that it has uncovered...
Jun 15, 2020 07:00 am ET
Applied Therapeutics Announces Start of AT-007 Pediatric Galactosemia Study; Releases Additional 40mg/kg Data from Adult Galactosemia Study
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced additional...
Jun 08, 2020 07:00 am ET
Applied Therapeutics to Present Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at 2020 American Diabetes Association Virtual Scientific Sessions
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that three abstracts...
Jun 03, 2020 07:00 am ET
Applied Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present...
May 26, 2020 07:00 am ET
Applied Therapeutics Announces Appointment of Dr. Chuck Silberstein, MD, MBA, CFA as Chief Financial Officer and Head of Business Development
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today the appointment of...
May 12, 2020 07:00 am ET
Applied Therapeutics to Present at the UBS Global Healthcare Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present...
May 11, 2020 07:00 am ET
Applied Therapeutics Reports First Quarter 2020 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Apr 21, 2020 07:00 am ET
Applied Therapeutics Announces Full Data and Scientific Presentations from the Pivotal Phase 2 ACTION-Galactosemia Trial
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced new data and...
Apr 02, 2020 07:00 am ET
Applied Therapeutics Announces IND and Investigator-Initiated Studies of AT-001 in Critical COVID-19 Patients
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that a COVID-19 IND...
Mar 13, 2020 07:00 am ET
Applied Therapeutics Reports Fourth Quarter and Year-end 2019 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for...
Mar 10, 2020 07:00 am ET
Applied Therapeutics to Present at the Barclays Global Healthcare Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present...
Mar 03, 2020 07:00 am ET
Applied Therapeutics Appoints Adam Hansard as Chief Commercial Officer
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today announced the appointment of Adam Hansard as Chief Commercial Officer. Mr....
Feb 26, 2020 04:05 pm ET
Applied Therapeutics to Present at the Cowen and Company 40th Annual Health Care Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present...
Jan 28, 2020 12:24 pm ET
Applied Therapeutics, Inc. Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares of Common Stock
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it...
Jan 23, 2020 09:28 pm ET
Applied Therapeutics, Inc. Announces Upsizing and Pricing of Public Offering of 2,741,489 Shares of Common Stock
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the...
Jan 21, 2020 04:16 pm ET
Applied Therapeutics, Inc. Announces Offering of 1,750,000 Shares of Common Stock
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that...
Jan 08, 2020 07:00 am ET
Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced positive topline...
Dec 16, 2019 07:00 am ET
Applied Therapeutics to Ring Nasdaq Closing Bell on December 17th
Applied Therapeutics Inc. (Nasdaq:APLT), announced today that Shoshana Shendelman, Ph.D., Founder, Chief Executive Officer and Chair of the Board, will ring the Nasdaq Closing Bell on Tuesday, December 17, 2019, at 4:00 p.m. ET. The ceremony will...
Dec 06, 2019 07:00 am ET
Applied Therapeutics Announces Presentation of Pre-Clinical Data Highlighting AT-001 for Treatment of Diabetic Cardiomyopathy at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Dis
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the presentation of...
Dec 05, 2019 07:00 am ET
Applied Therapeutics Announces Presentations Outlining the Design and Rationale for the ARISE-HF Pivotal Study of AT-001 for Treatment of Diabetic Cardiomyopathy at the 16th Annual Global Cardiovascul
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster and oral...
Nov 15, 2019 07:00 am ET
Applied Therapeutics Announces Presentation of Clinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the American Heart Association (AHA) Scientific Sessions 2019
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the presentation of...
Nov 13, 2019 07:00 am ET
Applied Therapeutics Reports Third Quarter 2019 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2019. “The...
Nov 12, 2019 07:00 am ET
Applied Therapeutics, Inc. Announces Pricing of $20 Million Private Placement of Common Stock
Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced it...
Oct 16, 2019 07:00 am ET
Applied Therapeutics to Present Data Highlighting AT-007 for the Treatment of Galactosemia at the American Society of Human Genetics (ASHG) 2019 Annual Meeting
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the Company will give...
Sep 17, 2019 07:00 am ET
Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced presentation of data...
Sep 13, 2019 07:00 am ET
Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced presentation of data...
Sep 04, 2019 07:00 am ET
Applied Therapeutics Announces Initiation of Phase 3 Registrational Trial of AT-001 in Diabetic Cardiomyopathy (ARISE-HF)
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a Phase 3...
Aug 28, 2019 07:00 am ET
Applied Therapeutics to Present at Baird’s 2019 Global Healthcare Conference
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, announced today that it will present at Baird’s 2019 Global Healthcare Conference on...
Aug 12, 2019 07:00 am ET
Applied Therapeutics Reports Second Quarter 2019 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2019. “During...
Aug 08, 2019 07:00 am ET
Applied Therapeutics Reports AT-007 SAD Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Study
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today announced the completion of the Single Ascending Dose (SAD) healthy volunteer...
Jun 24, 2019 07:00 am ET
Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a...
Jun 21, 2019 07:00 am ET
Applied Therapeutics Reports First Quarter 2019 Financial Results
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today reported financial results for the first quarter ended March 31, 2019. “Since...
Jun 07, 2019 07:30 am ET
Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy in Late Breaking Session at the American Diabetes Association 79th Annual Scientific Sessions
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present...
May 28, 2019 07:30 am ET
Applied Therapeutics Announces FDA Orphan Drug Designation for AT-007 in Galactosemia
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and...
May 24, 2019 07:00 am ET
Applied Therapeutics to Present Data at ESC-HF Highlighting AT-001, a Novel, Potent and Selective Aldose Reductase Inhibitor for Treatment of Diabetic Cardiomyopathy
Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.